

Agreement, Patient association "Organisation"

by and between

CSL Behring AB Box 712, 182 17 DANDERYD, SWEDEN 556530-1974

and

Danmarks Bløderforening Kompagnistraede 22, 2 sal. 1208 Kobenhavn, Denmark

1. Background

The purpose of this cooperation agreement is to contribute to the development of the association and to mutual exchange of experience with the association, as well as to support the association's activities in Denmark

2. Collaboration project

This cooperation agreement aims to ensure the development and exchange of experience in hemorrhagic diseases Hemophilia A and B and von Willebrand's disease in Denmark as well as providing support to the association's activities in Denmark.

CSL Behring AB has decided to support with a total sum of 78.250 DKK as followed:

- Sponsor the association's annual meeting – anniversary meeting in Horsens 33.000 DKK
- Sponsor a Portrait film about bleeding 20.250 DKK
- Full page ad in Blødernyt - themed new treatments 25.000 DKK

3. Finances

- 3.1 CSL Behring AB has undertaken to finance with 78.250 DKK in regard to what has been stated in point 2. Collaboration project. Payment against separate invoice.

4. Transparency

- 4.1 The Parties are in agreement that the contents of this Agreement may be communicated to a third party, which shall also be entitled to access the agreement.

- 4.2 For Sweden only: The Parties are in agreement that a short version of this agreement will be published in LIF's Collaboration database in accordance with Article 43.4 of the Ethical Rules for the Pharmaceutical Industry in Sweden.

5. Consultation, evaluation

- 5.1 Danmarks Bløderforening has appointed **Karen Binger Holm** as its contact person in matters concerning this Agreement.
- 5.2 CSL Behring AB has appointed **Mette Toft Jacobsen** as its contact person in matters concerning this Agreement.
- 5.3 Once the activity has been completed, the Parties shall jointly evaluate the events and their collaboration in relation to this project.

6. Agreement period and early termination

- 6.1 This Agreement is in force from 31/Jan/2020 until 31/Dec/2020.
- 6.2 If either party to a substantial degree fails to fulfil their obligations pursuant to this Agreement, and they do not make adjustments within thirty (30) days of being requested in writing to do so, the other party is entitled to immediately terminate the Agreement.

7. Ethical rules and law

- 7.1 Ethical rules and national law apply to this agreement. Danmarks Bløderforening warrants that it will only use the money received in accordance with national law and the Ethical Rules for the Pharmaceutical Industry.
- 7.2 Danmarks Bløderforening may not refer to or make any representation relating to CSL Behring or its products or the co-operation under this agreement without CSL Behring's prior written approval.
Danmarks Bløderforening shall submit all proposed materials mentioning or referring to CSL Behring or its products or the co-operation under this agreement to CSL Behring for its written approval prior to publication or use.

8. Disputes

If a dispute arises due to this Agreement, the Parties shall primarily attempt to resolve it through negotiation. In the event that the Parties are unable to reach an accord within thirty (30) days after negotiations have been called for by one party, the dispute shall be resolved in a Swedish Court.


This Agreement has been produced in two (2) identical copies, of which each party has taken one.

Place and Date: Danderyd,
CSL Behring AB: 4/2 -20



Name and title:
Petter Olbe
Marketing Manager, Nordic Region

Place and Date:
Danmarks Bløderforening: 21/4 -2020



Name and title:
Karen Binger Holm
Sekretariatsleder

Place and Date: Danderyd,
CSL Behring AB: 5/2 - 20



Name and title:
Martin Tenlen
General Manager, Nordic Region